Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observational, Multicenter Cohort Study Evaluating the Efficacy and Safety of NEPA (Netupitant/Palonosetron) in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

NCT07132749 is registered in ClinicalTrials.gov with Yeon Hee Park as lead sponsor.

NCT NCT07132749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07132749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observational, Multicenter Cohort Study Evaluating the Efficacy and Safety of NEPA (Netupitant/Palonosetron) in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd
Lead sponsor
Yeon Hee Park
Phase
Observational
Overall status
Enrolling by invitation
Start date
August 12, 2025
Completion date
September 30, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with her2-low advanced breast cancer treated with t-dxd, patients with her2-positive advanced breast cancer treated with t-dxd